These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 19297285)
1. Combination treatment for chronic HCV hepatitis in lymphangioleiomyomatosis: first case report. Bartalesi F; Camiciottoli G; Corti G; Maluccio NM; Biliotti E; Bartoloni A; Taliani G J Chemother; 2009 Feb; 21(1):110-1. PubMed ID: 19297285 [No Abstract] [Full Text] [Related]
2. Use of PEG-interferon alfa-2a plus ribavirin as treatment for chronic HCV hepatitis in a child cured of ALL. Lo Nigro L; La Spina M; Mirabile E; Pisana P; Schilirò G; Guardo P Pediatr Blood Cancer; 2004 Aug; 43(2):185. PubMed ID: 15236293 [No Abstract] [Full Text] [Related]
3. Boceprevir for HCV in patients with HIV: where next? Osinusi A; Naggie S Lancet Infect Dis; 2013 Jul; 13(7):563-4. PubMed ID: 23768748 [No Abstract] [Full Text] [Related]
4. The substantial role of initial ribavirin dose on the response to peginterferon alpha/ribavirin therapy in patients with genotype 1b chronic hepatitis C. Dai CY; Huang CF; Chuang WL; Huang JF; Yu ML Am J Gastroenterol; 2009 Sep; 104(9):2358-9. PubMed ID: 19727098 [No Abstract] [Full Text] [Related]
5. Do differences in pegylation of interferon alfa matter? Zeuzem S Gastroenterology; 2010 Jan; 138(1):34-6. PubMed ID: 19932662 [No Abstract] [Full Text] [Related]
6. [Chronic hepatitis C. First treatment]. Colombato L; Descalzi V; Gadano A Acta Gastroenterol Latinoam; 2005 Jun; 35 Suppl 1():S37-9. PubMed ID: 20214297 [No Abstract] [Full Text] [Related]
7. One step forward in understanding the differences in antiviral response to interferon a2a and a2b in chronic hepatitis C patients with advanced fibrosis. Shouval D J Hepatol; 2012 Feb; 56(2):303-4. PubMed ID: 22015961 [No Abstract] [Full Text] [Related]
8. Which is the real efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in HCV infected patients with advanced fibrosis? Pellicelli AM; Romano M; Guarascio P; Vignally P J Hepatol; 2012 Sep; 57(3):704-5. PubMed ID: 22510262 [No Abstract] [Full Text] [Related]
10. Age and prediction of sustained virological response to hepatitis C virus (HCV) infection treatment based on 28-day decrease in HCV RNA levels. Antonucci G; Angeletti C; Vairo F; Longo MA; Girardi E J Infect Dis; 2009 Nov; 200(9):1484-5; author reply 1485. PubMed ID: 19817588 [No Abstract] [Full Text] [Related]
15. Progress on the treatment of hepatitis C. Nierengarten MB Lancet Infect Dis; 2003 Dec; 3(12):748. PubMed ID: 14664249 [No Abstract] [Full Text] [Related]
16. Peginterferon alfa-2b plus ribavirin for chronic hepatitis. Santin M; Shaw E Lancet; 2002 Jan; 359(9302):263; author reply 264. PubMed ID: 11812596 [No Abstract] [Full Text] [Related]
17. [Healing of chronic hepatitis C following 12 weeks of therapy with peginterferon-alpha and ribavirin]. Barreales M; Castellano G; Fernández I; Muñoz R; Manzano M; Solís Herruzo JA Rev Esp Enferm Dig; 2007 Dec; 99(12):738-40. PubMed ID: 18290706 [No Abstract] [Full Text] [Related]
18. Peginterferon alfa-2b plus ribavirin for chronic hepatitis. Picon PD; Costa AF; Kuchenbecker R; Beltrame A Lancet; 2002 Jan; 359(9302):263; author reply 264. PubMed ID: 11812597 [No Abstract] [Full Text] [Related]